The AcrAB RND efflux system from the live vaccine strain of Francisella tularensis is a multiple drug efflux system that is required for virulence in mice

FEMS Microbiology Letters
Xiaowen R BinaJames E Bina

Abstract

The ability of bacterial pathogens to infect and cause disease is dependent upon their ability to resist antimicrobial components produced by their host, such as bile acids, fatty acids and other detergent-like molecules, and products of the innate immune system (e.g. cationic antimicrobial peptides). Bacterial resistance to the antimicrobial effects of such compounds is often mediated by active efflux systems belonging to the resistance-nodulation-division (RND) family of transporters. RND efflux systems have been implicated in antibiotic resistance and virulence extending their clinical relevance. In this report the hypothesis that the Francisella tularensis AcrAB RND efflux system contributes to antimicrobial resistance and pathogenesis has been tested. A null mutation was generated in the gene encoding the AcrB RND efflux pump protein of the live vaccine strain of F. tularensis. The resulting mutant exhibited increased sensitivity to multiple antibiotics and antimicrobial compounds. Murine challenge experiments revealed that the acrB mutant was attenuated. Collectively these results suggest that the F. tularensis AcrAB RND efflux system encodes a multiple drug efflux system that is important for virulence.

References

Oct 11, 1979·The New England Journal of Medicine·S M TeutschA F Kaufmann
May 1, 1989·Reviews of Infectious Diseases·A Tärnvik
Mar 1, 1987·European Journal of Epidemiology·D GrecoS Luzi
Jan 1, 1985·Scandinavian Journal of Infectious Diseases·H SyrjäläA Salminen
Dec 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J T Cross, R F Jacobs
Sep 1, 1995·Antimicrobial Agents and Chemotherapy·X Z LiK Poole
Oct 9, 1998·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M KarthausH Jürgens
Jun 29, 2001·Seminars in Cell & Developmental Biology·M H Saier, I T Paulsen
Jul 3, 2002·The Journal of Experimental Medicine·Yoichi HirakataDavid P Speert
Oct 5, 2002·Clinical Microbiology Reviews·Jill EllisRichard W Titball
Jan 14, 2003·Annual Review of Biochemistry·Hiroshi KadokuraJon Beckwith
Nov 6, 2004·Applied and Environmental Microbiology·Thomas H KawulaRobin R Craven
Dec 3, 2004·Applied and Environmental Microbiology·Tamara M MaierThomas C Zahrt
Dec 8, 2004·FEBS Letters·Juan Fernandez-RecioBen Luisi
May 11, 2005·Molecular Microbiology·Tracy L Raivio
Aug 10, 2005·Journal of Molecular Microbiology and Biotechnology·Jeremy Felce, Milton H Saier
Dec 20, 2005·Molecular Microbiology·Kunihiko NishinoEduardo A Groisman
Sep 1, 1936·Journal of Bacteriology·S P Karpoff, N I Antonoff
Apr 14, 2006·Cellular Microbiology·Anthony M BuckleyLaura J V Piddock
Apr 15, 2006·Clinical Microbiology Reviews·Laura J V Piddock
Jun 29, 2006·Archives of Microbiology·James E BinaJohn J Mekalanos
Jul 18, 2006·Nature Reviews. Microbiology·Laura J V Piddock
Aug 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Horacio GilDavid G Thanassi
Aug 24, 2006·Infection and Immunity·Rebecca TempelFred Heffron
Mar 29, 2007·Proceedings of the National Academy of Sciences of the United States of America·David S WeissDenise M Monack
Mar 31, 2007·Annals of the New York Academy of Sciences·Anders Sjöstedt
Apr 11, 2007·Infection and Immunity·Jingliang SuJing-Ren Zhang

❮ Previous
Next ❯

Citations

Sep 15, 2010·The Journal of Antimicrobial Chemotherapy·Brieuc GestinMax Maurin
Aug 22, 2013·The Journal of Antimicrobial Chemotherapy·Vivien SuteraMax Maurin
Nov 16, 2011·Antimicrobial Agents and Chemotherapy·Ida M ListerStuart B Levy
Feb 1, 2012·Antimicrobial Agents and Chemotherapy·Astrid PérezGermán Bou
Mar 22, 2012·MBio·Mark EnstromColin Manoil
Dec 1, 2009·Microbiology and Molecular Biology Reviews : MMBR·Roger D PechousThomas C Zahrt
Jun 13, 2012·Microbiology and Molecular Biology Reviews : MMBR·Crystal L JonesDavid S Weiss
Apr 27, 2010·BMC Microbiology·Saira AhmadMonique L van Hoek
Apr 7, 2010·PLoS Pathogens·Laura CamarenaMichael Snyder
Oct 19, 2012·Future Microbiology·Elodie RamondAlain Charbit
Nov 19, 2014·Future Microbiology·Jessica M A BlairLaura J V Piddock
Feb 10, 2016·Frontiers in Microbiology·Kathleen LoughmanJoseph Horzempa
Jan 8, 2016·The Lancet Infectious Diseases·Max Maurin, Miklós Gyuranecz
May 25, 2011·Microbial Pathogenesis·Nicole M Ark, Barbara J Mann
Aug 12, 2009·Current Opinion in Microbiology·Jessica M A Blair, Laura J V Piddock
Sep 13, 2012·Molecular Microbiology·Anna C LlewellynDavid S Weiss
May 24, 2011·Journal of Proteomics·Jiri DreslerJiri Stulik
Feb 12, 2009·FEMS Microbiology Reviews·Jose Luis MartinezCarolina Alvarez-Ortega
Jun 4, 2016·Colloids and Surfaces. B, Biointerfaces·Shams Tabrez KhanAbdulaziz A Al-Khedhairy
Apr 5, 2013·Clinical Microbiology Reviews·Alejandro BeceiroGermán Bou
Jul 15, 2020·Infection and Immunity·Kevin S GipsonChristina S Faherty
Apr 27, 2017·Frontiers in Cellular and Infection Microbiology·Yvan Caspar, Max Maurin
Jun 1, 2021·Frontiers in Microbiology·Stephen J Kassinger, Monique L van Hoek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.